

AMENDMENT TO THE CLAIMS

This claim listing will replace all prior versions, and listings, of the claims in the application. Claims 31-34 and 36-39 stand rejected. Claims 50-69 and 71-74 are allowed. Claims 35 and 70 are objected to.

1 - 30. (Cancelled)

31. (Previously presented) An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding human B7, said compound comprising at least an 8-nucleobase portion of SEQ ID NO: 256.

32. (Previously presented) The antisense compound of claim 31 which is an antisense oligonucleotide.

33. (Previously presented) The antisense compound of claim 32 which is modified.

34. (Previously presented) The antisense compound of claim 31 which is between 18 and 30 nucleobases in length.

35. (Previously presented) The antisense compound of claim 31 comprising SEQ ID NO: 256.

36. (Previously presented) The antisense compound of claim 32 which comprises at least one modified internucleoside linkage.

37. (Previously presented) The antisense compound of claim 36 wherein the modified internucleoside linkage is a phosphorothioate linkage.

38. (Previously presented) The antisense compound of claim 37 wherein every internucleoside linkage is a phosphorothioate linkage.

39. (Previously presented) The antisense compound of claim 32 which comprises at least one modified sugar moiety.

40. (Previously presented) The antisense compound of claim 39 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

41. (Previously presented) The antisense compound of claim 32 which comprises at least one modified nucleobase.

42. (Previously presented) The antisense compound of claim 41 wherein the modified nucleobase is a 5-methylcytosine.

43. (Currently amended) The antisense compound of claim 41 wherein nucleobases 1-4 1-5 and 15-18 16-20 comprise a 2'-O-methoxyethyl modification.

44. (Previously presented) The antisense compound of claim 41, wherein each cytidine residue comprises a 5-methyl modification.

45. (Previously presented) The antisense compound of claim 31, that is a pharmaceutically acceptable salt.

46. (Previously presented) The antisense compound of claim 45 that is a sodium salt.

47. (Previously presented) A composition comprising the antisense compound of claim 31 in combination with a carrier or diluent.

48. (Previously presented) The composition of claim 47 further comprising a colloidal dispersion system.

49. (Previously presented) The composition of claim 47 further comprising an anti-inflammatory or immunosuppressive agent.

50. (Previously presented) A composition comprising an antisense compound consisting of SEQ ID NO: 256.

51. (Previously presented) The composition of claim 50, wherein every internucleoside linkage of the antisense compound is a phosphorothioate linkage.

52. (Previously presented) The composition of claim 50, wherein each cytidine residue of the antisense compound comprises a 5-methyl modification.

53. (Previously presented) The composition of claim 50, wherein the antisense compound is a pharmaceutically acceptable salt.

54. (Previously presented) The composition of claim 53 wherein the pharmaceutically acceptable salt is a sodium salt.

55. (Previously presented) The composition of claim 50 further comprising a pharmaceutically acceptable carrier or diluent.

56. (Previously presented) The composition of claim 53 further comprising a pharmaceutically acceptable carrier or diluent.

57. (Currently amended) A composition comprising an antisense compound comprising SEQ ID NO: 256, wherein every internucleoside linkage is a phosphorothioate linkage, and nucleobases 4-4 1-5 and 15-18 16-20 comprise a 2'-O-methoxyethyl modification.

58. (Previously presented) The composition of claim 57, wherein each cytidine residue of the antisense compound comprises a 5-methyl modification.

59. (Previously presented) The composition of claim 58, wherein the antisense compound is a pharmaceutically acceptable salt.

60. (Previously presented) The composition of claim 59, wherein the pharmaceutically acceptable salt is a sodium salt.

61. (Previously presented) The composition of claim 57, further comprising a pharmaceutically acceptable carrier or diluent.

62. (Previously presented) The composition of claim 61 further comprising a pharmaceutically acceptable carrier or diluent.

63. (Currently amended) A composition comprising an antisense compound consisting of SEQ ID NO: 256, wherein every internucleoside linkage is a phosphorothioate linkage, and nucleobases 1-4 1-5 and 15-18 16-20 comprise a 2'-O-methoxyethyl modification.

64. (Previously presented) The composition of claim 63, wherein each cytidine residue of the antisense compound comprises a 5-methyl modification.

65. (Previously presented) The composition of claim 64, wherein the antisense compound is a pharmaceutically acceptable salt.

66. (Previously presented) The composition of claim 65, wherein the pharmaceutically acceptable salt is a sodium salt.

67. (Previously presented) The composition of claim 63, further comprising a pharmaceutically acceptable carrier or diluent.

68. (Previously presented) The composition of claim 65, further comprising a pharmaceutically acceptable carrier or diluent.

69. (Previously presented) A composition comprising an antisense compound consisting of SEQ ID NO: 256, wherein every internucleoside linkage is a phosphorothioate linkage, nucleobases 1-4 and 15-18 comprise a 2'-O-methoxyethyl modification, and cytidine residues at positions 5 and 10 comprise a 5-methyl modification.

70. (Cancelled)

71. (Previously presented) The composition of claim 69, wherein the compound is a pharmaceutically acceptable salt.

72. (Previously presented) The composition of claim 71, wherein the pharmaceutically acceptable salt is a sodium salt.

73. (Previously presented) The composition of claim 69, further comprising a pharmaceutically acceptable carrier or diluent.

74. (Previously presented) The composition of claim 71, further comprising a pharmaceutically acceptable carrier or diluent.